|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | New generation of multi-scale NWP system (GRAPES):general scientific design显示文摘A new generation of numerical prediction system GRAPES (a short form of Global/Regional Assimilation and PrEdiction System) was set up in China Meteorological Administration (CMA). This paper focuses on the scientific design and preliminary results of the numerical prediction model in GRAPES, including basic idea and strategy of the general scientific design, multi-scale dynamic core, physical package configuration, architecture and parallelization of the codes. A series of numerical experiments using the real data with horizontal resolutions from 10 to 280 km and idealized experiments with very high resolution up to 100 m are conducted, giving encouraging results supporting the multi-scale application of GRAPES. The results of operational implementation of GRAPES model in some NWP centers are also presented with stress at evaluations of the capability to predict the main features of precipitation in China. Finally the issues to be dealt with for further development are discussed. | CHEN DeHui XUE JiShan YANG XueSheng ZHANG HongLiang SHEN XueShun HU JiangLin WANG Yu JI LiRen CHEN JiaBin | 2008 | Chinese Science Bulletin2008，53，22： | 70 |
| 2 | HIF-1α-induced expression of m6A reader YTHDF1 drives hypoxia-induced autophagy and malignancy of hepatocellular carcinoma by promoting ATG2A and ATG14 translation显示文摘N6-methyladenosine(m6A),and its reader protein YTHDF1,play a pivotal role in human tumorigenesis by affecting nearly everystage of RNA metabolism.Autophagy activation is one of the ways by which cancer cells survive hypoxia.However,the possibleinvolvement of m6A modification of mRNA in hypoxia-induced autophagy was unexplored in human hepatocellular carcinoma(HCO).In this study,specific variations in YTHDF1 expression were detected in YTHDF1-overexpressing,knockout,and-knockdownHCC cells,HCC organoids,and HCC patient-derived xenograft(PDX)murine models.YTHDF1 expression and hypoxia inducedautophagy were significantly correlated in vitro;signifhcant overexpression of YTHDF1 in HCC tissues was associated with poorprognosis,Multivariate cox regression analysis identihed YTHDF1 expression as an independent prognostic factor in patients withHCC.Multiple HC models conhrmed that YTHDF1 deficiency inhibited HCC autophagy,growth,and metastasis.Luciferase reporterassays and chromatin immunoprecipitation demonstrated that HlIF-1a regulated YTHDF1 transcription by directly binding to itspromoter region under hypoxia.The results of methylated RNA immunoprecipitation sequencing,proteomics,and polysomeprofling indicated that YTHDF1 contibuted to the translation of autophagy-related genes ATG2A and ATG14 by binding to m6A-modifhed ATG2A and ATG14 mRNA,thus facilitating autophagy and autophagy-related malignancy of HCC.Taken together,HlE-1d-induced YTHDF1 expression was associated with hypoxia-induced autophagy and autophagy-related HCC progression via promoting translation of autophagy-related genes ATG2A and ATG14 in a m6A-dependent manner.Our fndings suggest thatYTHDF1 is a potential prognostic biomarker and therapeutic target for patients with HCC. | Qing Li Yong Ni Liren Zhang Runqiu Jiang Jing Xu Hong Yang Yuanchang Hu Jiannan Qiu Liyong Pu Jinhai Tang Xuehao Wang | 2021 | Signal Transduction and Targeted Therapy2021，6，3： | 24 |
| 3 | Reactivation of γ-globin expression through Cas9 or base editor to treat β-hemoglobinopathies显示文摘Dear Editor,Mutations in the β-globin gene,the essential component of adult hemoglobin(HbA;a2p2),results in either a production of aberrant sickle hemoglobin(HbS)leading to sickle cell disease(SCD)or an insufficient β-globin synthesis leading to β-thalassemia.These two major forms of β-hemoglobinopathies cause impaired erythropoiesis and life-threatening anemia.Clinical evidence has suggested that reaaivation of fetal γ-globin(HBG)gene expression which is normally silenced after birth by certain genetic mutations can ameliorate the clinical course of β-hemoglobinopathies. | Liren Wang Linxi Li Yanlin Ma Handan Hu Qi Li Yang Yang Wenbang Liu Shuming Yin Wei Li Bin Fu Ryo Kurita Yukio Nakamura Mingyao Liu Yongrong Lai Dali Li | 2020 | Cell Research2020，30，3： | 14 |
| 4 | Increasing targeting scope of adenosine base editors in mouse and rat embryos through fusion of TadA deaminase with Cas9 variants显示文摘 | Lei Yang Xiaohui Zhang Liren Wang Shuming Yin Biyun Zhu Ling Xie Qiuhui Duan Huiqiong Hu Rui Zheng Yu Wei Liangyue Peng Honghui Han Jiqin Zhang Wenjuan Qiu Hongquan Geng Stefan Siwko Xueli Zhang Mingyao Liu Dali Li | 2018 | Protein & Cell2018，9，9： | 13 |
| 5 | CRISPR/Cas9 system: a powerful technology for in vivo and ex vivo gene therapy显示文摘CRISPR/Cas9 is a versatile genome-editing tool which is widely used for modifying the genome of both prokaryotic and eukaryotic organisms for basic research and applications. An increasing number of reports have demonstrated that CRISPR/Cas9-mediated genome editing is a powerful technology for gene therapy. Here, we review the recent advances in CRISPR/Cas9-mediated gene therapy in animal models via different strategies and discuss the challenges as well as future prospects. | Xiaohui Zhang Liren Wang Mingyao Liu Dali Li | 2017 | Science China(Life Sciences)2017，60，5： | 12 |
| 6 | Gene editing and its applications in biomedicine显示文摘The steady progress in genome editing, especially genome editing based on the use of clustered regularly interspaced short palindromic repeats(CRISPR) and programmable nucleases to make precise modifications to genetic material, has provided enormous opportunities to advance biomedical research and promote human health. The application of these technologies in basic biomedical research has yielded significant advances in identifying and studying key molecular targets relevant to human diseases and their treatment. The clinical translation of genome editing techniques offers unprecedented biomedical engineering capabilities in the diagnosis, prevention, and treatment of disease or disability. Here, we provide a general summary of emerging biomedical applications of genome editing, including open challenges. We also summarize the tools of genome editing and the insights derived from their applications, hoping to accelerate new discoveries and therapies in biomedicine. | Guanglei Li Xiangyang Li Songkuan Zhuang Liren Wang Yifan Zhu Yangcan Chen Wen Sun Zeguang Wu Zhuo Zhou Jia Chen Xingxu Huang Jin Wang Dali Li Wei Li Haoyi Wang Wensheng Wei | 2022 | Science China(Life Sciences)2022，65，4： | 8 |
| 7 | Total mesorectal excision with or without preoperative chemoradiotherapy for resectable mid/low rectal cancer: a long-term analysis of a prospective, single-center, randomized trial显示文摘Background:The preliminary results of our phase II randomized trial reported comparable functional sphincter pres-ervation rates and short-term survival outcomes between patients undergoing total mesorectal excision(TME)with or without preoperative concurrent chemoradiotherapy(CCRT).We now report the long-term results after a median follow-up of 71 months.Methods:Between March 23,2008 and August 2,2012,192 patients with T3-T4 or node-positive,resectable,mid/low rectal adenocarcinoma were randomly assigned to receive TME with or without preoperative CCRT.The following endpoints were assessed:cumulative rates of local recurrence and distant metastasis,disease-free survival(DFS),and overall survival(OS).Results:The data of 184 eligible patients were analyzed:94 patients in the TME group and 90 patients in the CCRT+TME group.In the whole cohort,the 5-year DFS and OS rates were 84.8%and 85.1%,respectively.The 5-year DFS rates were 85.2%in the CCRT+TME group and 84.3%in the TME group(P=0.969),and the 5-year OS rates were 83.5%in the CCRT+TME group and 86.5%in the TME group(P=0.719).The 5-year cumulative rates of local recur-rence were 6.3%and 5.0%(P=0.681),and the 5-year cumulative rates of distant metastasis were 15.0%and 15.7%(P=0.881)in the CCRT+TME and TME groups,respectively.No significant improvements in 5-year DFS and OS were observed with CCRT by subgroup analyses.Conclusions:Both treatment strategies yielded similar long-term outcomes.A selective policy towards preoperative CCRT is thus recommended for rectal cancer patients if high-quality TME surgery and enhanced chemotherapy can be performed. | Fulong Wang Wenhua Fan Jianhong Peng Zhenhai Lu Zhizhong Pan Liren Li Yuanhong Gao Hui Li Gong Chen Xiaojun Wu Peirong Ding Zhifan Zeng Desen Wan | 2018 | Cancer Communications2018，38，1： | 6 |
| 8 | 对可切除的中/低位直肠癌是/否进行术前放化疗的全直肠系膜切除术研究:一项前瞻性、单中心、随机试验的长期分析显示文摘背景与目的我们的Ⅱ期随机试验的初步研究结果显示,对进行全直肠系膜切除术(total mesorectal excision,TME)的患者是/否进行术前同步放化疗(concurrent chemoradiotherapy,CCRT),二者的功能性括约肌保留率和短期生存结局相近。在经过中位71个月的随访后,现报告这一长期试验的结果。方法在2008年3月23日至2012年8月2日期间,192例患有T3–T4或淋巴结阳性、可切除的中/低直肠腺癌患者被随机分为接受或不接受术前CCRT组,之后均进行TME。评估以下终点:局部复发和远处转移的累积率、无病生存(disease?free survival,DFS)和总生存(overall survival,OS)。结果对入组的184例患者资料进行分析,其中TME组有94例,CCRT+TME组有90例。在整个队列中,5年DFS和OS率分别为84.8%和85.1%。CCRT+TME组的5年DFS率为85.2%,TME组为84.3%(P=0.969);CCRT+TME组的5年OS率为83.5%,TME组为86.5%(P=0.719)。在CCRT+TME和TME组中,局部复发的5年累积率分别为6.3%和5.0%(P=0.681),远处转移的5年累积率分别为15.0%和15.7%(P=0.881)。通过亚组分析,接受CCRT未观察到5年DFS和OS的显著改善。结论两种治疗方案的长期结局相近。因此,如果可以进行高质量的TME手术和强化化疗,建议选择性地对直肠癌患者进行术前CCRT。 | Fulong Wang Wenhua Fan Jianhong Peng Zhenhai Lu Zhizhong Pan Liren Li Yuanhong Gao Hui Li Gong Chen Xiaojun Wu Peirong Ding Zhifan Zeng Desen Wan | 2019 | 癌症2019，38，5： | 2 |
| 9 | Nature:研究鉴定出侵袭性胰腺癌细胞及其弱点显示文摘在一项新的研究中,来自美国德州大学MD安德森癌症中心的研究人员利用患者源性肿瘤异种移植(patient—derived tumorxenograft,PDx)和模式小鼠开展一系列临床前实验,鉴定出一种门卫蛋白(gatekee Perprotein)阻止胰腺癌细胞转化为一种极具侵袭性的细胞类型,并且也发现剔除这种门卫蛋白的疗法能够阻止这些癌细胞。这些发现有助为携带这种进展迅速的治疗抵抗性的胰腺癌细胞亚群的患者开发出潜在的疗法。 | Genovese, Giannicola Carugo, Alessandro Tepper, James Robinson, Frederick Scott Li, Liren Svelto, Maria Nezi, Luigi Corti, Denise Minelli, Rosalba Pettazzoni, Piergiorgio Gutschner, Tony Wu, Chia-Chin Seth, Sahil Akdemir, Kadir Caner Leo, Elisabetta Amin, Samirkumar Dal Molin, Marco Ying, Haoqiang Kwong, Lawrence N. Colla, Simona Takahashi, Koichi Ghosh, Papia Giuliani, Virginia Muller, Florian Dey, Prasenjit Jiang, Shan Garvey, Jill Liu, Chang-Gong Zhang, Jianhua Heffernan, Timothy P. Toniatti, Carlo Fleming, Jason B. Goggins, Michael G. Wood, Laura D. Sgambato, Alessandro Agaimy, Abbas Maitra, Anirban Roberts, Charles W. M. Wang, Huamin Viale, Andrea DePinho, Ronald A. Draetta, Giulio F. Chin, Lynda | 2017 | 现代生物医学进展2017，17，14： | 2 |
| 10 | Crimped nanofiber scaffold mimicking tendon-to-bone interface for fatty-infiltrated massive rotator cuff repair显示文摘Electrospun fibers,with proven ability to promote tissue regeneration,are widely being explored for rotator cuff repairing.However,without post treatment,the microstructure of the electrospun scaffold is vastly different from that of natural extracellular matrix(ECM).Moreover,during mechanical loading,the nanofibers slip that hampers the proliferation and differentiation of migrating stem cells.Here,electrospun nanofiber scaffolds,with crimped nanofibers and welded joints to biomimic the intricate natural microstructure of tendon-to-bone insertion,were prepared using poly(ester-urethane)urea and gelatin via electrospinning and double crosslinking by a multi-bonding network densification strategy.The crimped nanofiber scaffold(CNS)features bionic tensile stress and induces chondrogenic differentiation,laying credible basis for in vivo experimentation.After repairing a rabbit massive rotator cuff tear using a CNS for 3 months,the continuous translational tendon-to-bone interface was fully regenerated,and fatty infiltration was simultaneously inhibited.Instead of micro-CT,μCT was employed to visualize the integrity and intricateness of the three-dimensional microstructure of the CNS-induced-healed tendon-to-bone interface at an ultra-high resolution of less than 1μm.This study sheds light on the correlation between nanofiber post treatment and massive rotator cuff repair and provides a general strategy for crimped nanofiber preparation and tendon-to-bone interface imaging characterization. | Liren Wang Tonghe Zhu Yuhao Kang Jianguang Zhang Juan Du Haihan Gao Sihao Chen Jia Jiang Jinzhong Zhao | 2022 | Bioactive Materials2022，7，10： | 2 |
| 11 | Electrospinning Engineering Enables High‑Performance Sodium‑Ion Batteries显示文摘As a promising energy storage device,sodium-ion batteries(SIBs)have received continuous attention due to their low-cost and environmental friendliness.However,the sluggish kinetics of Na ion usually makes SIBs hard to realize desirable electrochemical performance when compared to lithium-ion batteries(LIBs).The key to addressing this issue is to build up nanostructured materials which enable fast Na-ion insertion/extraction.One-dimensional(1D)nanocarbons have been considered as both the anode and the matrix to support active materials for SIB electrodes owing to their high electronic conductivity and excellent mechanical property.Because of their large surface areas and short ion/electron difusion path,the synthesized electrodes can show good rate performance and cyclic stability during the charge/discharge processes.Electrospinning is a simple synthetic technology,featuring inexpensiveness,easy operation and scalable production,and has been largely used to fabricate 1D nanostructured composites.In this review,we frst give a simple description of the electrospinning principle and its capability to construct desired nanostructures with diferent compositions.Then,we discuss recent developments of carbon-based hybrids with desired structural and compositional characteristics as the electrodes by electrospinning engineering for SIBs.Finally,we identify future research directions to realize more breakthroughs on electrospun electrodes for SIBs. | Chuanping Li Min Qiu Ruiling Li Xuan Li Manxi Wang Jiabo He Ganggang Lin Liren Xiao Qingrong Qian Qinghua Chen Junxiong Wu Xiaoyan Li Yiu‑Wing Mai Yuming Chen | 2022 | Advanced Fiber Materials2022，4，1： | 1 |
| 12 | Binary encoded vector- matrix multiplication architecture 显示文摘 | Zhou Changhe Liu Liren Wang Zhijiang | 1992 | Opt Lett1992，，17： | 1 |
| 13 | Large- aperture double-focus laser collimator for PAT performance testing of inter-satellite laser communi- cation terminal显示文摘 | Lijuan Wang Liren Liu Jianfeng Sun Yu Zhou Zhu Luan De' an Liu | 2009 | Optik- International Journal for Light and Electron Optics2009，17，： | 1 |
| 14 | Platelet-rich Plasma Reverses the Inhibition of Tenocytes and Osteoblasts in Tendon-Bone Healing显示文摘 | Zhai Wenliang Wang Nan Qi Zhi Gao Quan Yi Liren | 2012 | EN2012，，4： | 1 |
| 15 | Optical dual self functions显示文摘 | Hua Jianwen Liu liren Wang ning | 1997 | Science in China (Series E)1997，40，6： | 1 |
| 16 | Blue upconversion of cubic Gd2 O3 : Er3+ produced by green laser显示文摘 | Guo Hai Li Yunfeng Wang Dianyuan Zhang Weiping Yin Min Lou Liren Xia Shangda | 2004 | Journal of Alloys andCompounds2004，376，： | 1 |
| 17 | Optical implementation of heteroassociative loop显示文摘 | Changhe Zhou Liren Liu Zhijiang Wang(Shanghai Institute of Optics and Fine Mechanics Academia Sinica P.O.Box 800-216 Shanghai 201800 China) | 1993 | Chinese Journal of Lasers1993，，03： | 1 |
| 18 | Primary tracheobronchial amyloidosis in China: Analysis of 64 cases and a review of literature显示文摘 | Liren Ding Wen Li Kai Wang Yahong Chen Hao Xu Huiying Wang Huahao Shen | 2010 | Journal of Huazhong University of Science and Technology2010，，5： | 1 |
| 19 | Binary-encoded vector-matrix multiplication architecture 显示文摘 | Zhou changhe Liu liren Wang zhijiang | 1992 | Opt Lett1992，，17： | 1 |
| 20 | Mefatinib as first-line treatment of patients with advanced EGFR-mutant non-small-cell lung cancer:a phase Ib/II efficacy and biomarker study显示文摘EGFR inhibitors have revolutionized the treatment of advanced non-small-cell lung cancer(NSCLC).Mefatinib is a novel,bioavailable,second-generation,irreversible pan-EGFR inhibitor.This phase Ib/II open-label,single-arm,multi-center study investigated the efficacy,safety,biomarker,and resistance mechanisms of mefatinib in the first-line treatment of patients with advanced EGFR-mutant NSCLC.This study included 106 patients with EGFR-mutant stage IIIB-IV NSCLC who received first-line mefatinib at a daily dose of either 60 mg(n=51)or 80 mg(n=55).The primary endpoint was progression-free survival(PFS).Secondary endpoints were overall response rate(ORR),disease control rate(DCR),overall survival(OS),and safety.The cohort achieved an ORR of 84.9%and DCR of 97.2%.The median PFS was 15.4 months and the median OS was 31.6 months.Brain metastasis was detected in 29%of patients(n=31)at diagnosis and demonstrated an ORR of 87.1%,PFS of 12.8 months,and OS of 25.2 months.Adverse events primarily involved skin and gastrointestinal toxicities,which were well-tolerated and manageable.Analyses of mutation profiles were performed using targeted sequencing of plasma samples at baseline,first follow-up 6 weeks from starting mefatinib therapy(F1),and at progression.Patients with concurrent TP53 mutations had comparable PFS as wild-type TP53(14.0 vs 15.4 months;p=0.315).Furthermore,circulating tumor DNA clearance was associated with longer PFS(p=0.040)and OS(p=0.002).EGFR T790M was the predominant molecular mechanism of mefatinib resistance(42.1%,16/38).First-line mefatinib provides durable PFS and an acceptable toxicity profile in patients with advanced EGFR-mutant NSCLC. | Pingli Wang Yuping Li Dongqing Lv Lingge Yang Liren Ding Jianya Zhou Wei Hong Youfei Chen Dongqing Zhang Susu He Jianying Zhou Kai Wang | 2021 | Signal Transduction and Targeted Therapy2021，6，12： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员